European Union - English - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.

European Union - English - EMA (European Medicines Agency)

genzyme europe bv - sevelamer hydrochloride - hyperphosphatemia; renal dialysis - all other therapeutic products - tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.,

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - powder for solution for injection/infusion - 50 milligram(s) - purine analogues; fludarabine

Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - fludarabine phosphate - powder for solution for infusion or injection - fludarabine phosphate 25 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - fludarabine phosphate - film-coated tablet - fludarabine phosphate 10 mg - antineoplastic agents

European Union - English - myHealthbox

genzyme therapeutics ltd - alemtuzumab - concentrate for solution for infusion - 12 mg alemtuzumab in 1.2 ml (10 mg/ml) - multiple sclerosis - selective immunosuppressants - indicated for adult patients with relapsing remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - imiglucerase - powder for solution for infusion - 400unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - agalsidase beta - powder for solution for infusion - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - agalsidase beta - powder for solution for infusion - 35mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alglucosidase alfa - powder for solution for infusion - 50mg